Accession Number : AD1049248


Title :   Defining Hepatocellular Carcinoma Subtypes and Treatment Responses in Patient-Derived Tumorgrafts


Descriptive Note : Technical Report,30 Sep 2016,29 Sep 2017


Corporate Author : UT Southwestern Medical Center Dallas United States


Personal Author(s) : Zhu, Hao ; Waljee,Akbar ; Singal,Amit ; Yopp,Adam ; Siegwart,Daniel


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1049248.pdf


Report Date : 01 Oct 2017


Pagination or Media Count : 13


Abstract : Hepatocellular carcinoma (HCC) is the 6th most common cancer and 3rd leading cause of cancer-related death worldwide. We know that HCC subtypes exist because clear clinical, radiographic, and histological differences between patients with HCC are observed. In this study we proposed to investigate distinct subtypes of HCC using a mouse-human chimeric Patient Derived Xenograft (PDX) approach. So far, we have performed a large effort to implant 102 tumors from human HCC patients from Texas. We have established the protocol and the results have taught us that engraftment using a variety of transplantation techniques will result in a 25-30% engraftment efficiency for early stage surgical tumors. We have established 6 new human HCC PDX models that will be highly relevant for therapeutic and biological studies. These represent North American HCCs, including some patients with intermediate/advanced stage HCC, which is a unique resource for the field.


Descriptors :   Carcinoma , neoplasms , ribonucleic acids , assays , biological markers


Subject Categories : Medicine and Medical Research
      Biochemistry


Distribution Statement : APPROVED FOR PUBLIC RELEASE